Inhibrx Biosciences (INBX) Other Non-Current Assets (2023 - 2026)

Inhibrx Biosciences (INBX) has reported Other Non-Current Assets for 3 consecutive years, with $4.4 million the latest figure, recorded in Q4 2025.

• In Q4 2025, Other Non-Current Assets fell 35.91% year-over-year to $4.4 million; the TTM figure through Dec 2025 stood at $4.4 million (down 35.91% YoY), while the FY2025 annual figure was $4.4 million, down 35.91% from the prior year.
• Other Non-Current Assets slipped to $4.4 million in Q4 2025 per INBX's latest filing, from $5.7 million in the prior quarter.
• Across five years, Other Non-Current Assets topped out at $6.8 million in Q4 2024 and bottomed at $3.2 million in Q4 2023.
• Historically, Other Non-Current Assets has averaged $5.9 million across 3 years, with a median of $6.7 million in 2024.
• Annual changes were most pronounced in 2024 — Other Non-Current Assets jumped 115.9% — and 2025, when it sank 35.91%.
• Inhibrx Biosciences' Other Non-Current Assets stood at $3.2 million in 2023, then surged by 115.9% to $6.8 million in 2024, then sank by 35.91% to $4.4 million in 2025.
• Business Quant data shows INBX's Other Non-Current Assets at $4.4 million in Q4 2025, $5.7 million in Q3 2025, and $6.8 million in Q2 2025.